Tian Yi Yi Zhang, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Zhang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A130597 · Current
Licensed to practise in California · since 2014 · expires 2027-08-31 · University of Utah School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$59,723
Medicare paid this office $59,723 for 139 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 55 | $17,142 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $15,592 | $105 |
| Long return visit (40+ min) | 41 | $13,517 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,565 | $155 |
| New patient visit (60+ min) | 15 | $2,449 | $163 |
See all 9 services
| Long return visit (40+ min) | 55 | $17,142 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $15,592 | $105 |
| Long return visit (40+ min) | 41 | $13,517 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,565 | $155 |
| New patient visit (60+ min) | 15 | $2,449 | $163 |
| Hospital discharge day management, more than 30 minutes | 24 | $2,432 | $101 |
| New patient visit (60+ min) | 14 | $2,432 | $174 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 30 | $689 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 31 | $524 | $15 |
Who their Medicare patients are
139 Original Medicare patients in 2024. Average age 74 · Women 46% · Also on Medicaid 24% · Health risk score 3.13. Above the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 71% · Chronic kidney disease 35% · Coronary heart disease 34% · Atrial fibrillation 31% · Diabetes 25% · Depression 24% · Cancer 23% · Heart failure 20% · COPD 17% · Stroke 14% · Dementia 13%.
The office billed $240,471, Medicare allowed $76,796 and paid $59,723; for 535 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 139 | 535 | 74 | 3.13 | $240,471 | $59,723 |
| 2023 | 115 | 460 | 73 | 2.92 | $224,778 | $51,845 |
| 2022 | 141 | 592 | 72 | 3.23 | $274,345 | $62,516 |
| 2021 | 105 | 518 | 74 | 2.96 | $243,652 | $57,667 |
| 2020 | 40 | 158 | 72 | 3.99 | $102,052 | $16,307 |
| 2019 | 38 | 128 | 74 | 3.04 | $18,948 | $11,728 |
| 2018 | 12 | 24 | 74 | 3.02 | $2,737 | $2,051 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 56 | $20,880 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $19,569 | $108 |
| Return visit (30+ min) | 29 | $3,569 | $87 |
| New patient visit (60+ min) | 20 | $3,059 | $153 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,165 | $144 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,821 | $101 |
2022: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $28,392 | $92 |
| Long return visit (40+ min) | 40 | $19,169 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,886 | $181 |
| Hospital discharge day management, more than 30 minutes | 19 | $2,058 | $98 |
| New patient visit (60+ min) | 13 | $2,019 | $155 |
| Return visit (30+ min) | 17 | $1,992 | $80 |
2021: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $24,056 | $95 |
| Long return visit (40+ min) | 37 | $14,028 | $126 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $7,614 | $186 |
| Return visit (30+ min) | 25 | $4,787 | $92 |
| Hospital discharge day management, more than 30 minutes | 26 | $2,927 | $101 |
| New patient visit (60+ min) | 13 | $2,235 | $172 |
2020: 3 services
| Long return visit (40+ min) | 27 | $11,980 | $101 |
| New patient visit (60+ min) | 11 | $1,698 | $154 |
| Long return visit (40+ min) | 12 | $1,661 | $104 |
2019: 2 services
| Long return visit (40+ min) | 24 | $5,571 | $99 |
| Return visit (30+ min) | 18 | $2,970 | $69 |
Medicaid work
$8,824 in 2022
Medicaid paid $8,824 for 168 billed services this clinician did in 2022, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 168 | $8,824 |
| 2022 | 168 | 1 | 15 | $8,824 |
| 2021 | 88 | 2 | 17 | $3,031 |
See the largest Medicaid services in earlier years
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 76 | $2,399 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $631 |
Drugs they prescribed that Part D paid
$709,465
Pharmacies billed $709,465 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
60 generic and 79 brand-name prescriptions · $709,465 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Venclexta | 45 | $134,888 | $2,998 |
| Cresemba | 11 | $63,343 | $5,758 |
Year by year
| 2024 | 139 | 35 | None | 57% | $709,465 |
| 2023 | 141 | 36 | 0% (0) | 33% | $479,825 |
| 2022 | 149 | 36 | None | 30% | $540,242 |
| 2021 | 125 | 35 | 0% (0) | 50% | $776,883 |
| 2020 | 55 | 19 | 0% (0) | 73% | $481,726 |
| 2019 | 94 | 18 | None | 35% | $418,220 |
| 2018 | 23 | 12 | 0% (0) | 52% | $150,850 |
| 2014 | 22 | 11 | None | None | $4,014 |
| 2013 | 27 | None | None | None | $1,108 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Venclexta | 29 | $127,548 | $4,398 |
| Acyclovir | 12 | $223 | $19 |
2022: 3 drugs
| Venclexta | 21 | $106,597 | $5,076 |
| Valacyclovir | 12 | $211 | $18 |
| Ondansetron | 11 | $84 | $8 |
2021: 3 drugs
| Idhifa | 13 | $371,282 | $28,560 |
| Venclexta | 31 | $241,202 | $7,781 |
| Cresemba | 12 | $66,674 | $5,556 |
2020: 1 drug
| Venclexta | 23 | $201,977 | $8,782 |
2019: 2 drugs
| Venclexta | 16 | $141,198 | $8,825 |
| Allopurinol | 13 | $123 | $9 |
Money from drug and device companies
$77 in 2025
| 2025 | 3 | 3 | None | $77 |
| 2024 | 1 | 1 | None | $997 |
| 2023 | 5 | 15 | $13,460 | $13,871 |
| 2022 | 4 | 7 | $2,076 | $2,468 |
| 2021 | 2 | 3 | None | $141 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Erleada | $34 | 1 payment
|
| Geron | Rytelo | $25 | 1 payment
|
| Coherus Oncology | Loqtorzi | $18 | 1 payment
|
See all 3 published payments
| Geron | Meals · 2025-10-30 | Rytelo | $25 |
| Janssen Biotech | Meals · 2025-10-18 | Erleada | $34 |
| Coherus Oncology | Meals · 2025-08-13 | Loqtorzi | $18 |
See earlier years (2024, 2023, 2022, 2021)
2024: $997
| Celgene | None | $997 | 1 payment
|
2023: $13,871
| Rigel Pharmaceuticals | Rezlidhia | $5,725 | 9 payments
|
| Servier Pharmaceuticals | Tibsovo | $4,317 | 3 payments
|
| Gilead Sciences | None | $3,780 | 1 payment
|
| AbbVie | Venclexta | $28 | 1 payment
|
| Celgene | Reblozyl | $21 | 1 payment
|
2022: $2,468
| E.R. Squibb & Sons L.L.C. | None | $2,076 | 1 payment
|
| Abbvie | Venclexta | $198 | 2 payments
|
| Celgene | Onureg | $159 | 3 payments
|
| Astellas Pharma US | Padcev | $34 | 1 payment
|
2021: $141
| E.R. Squibb & Sons L.L.C. | None | $71 | 1 payment
|
| AbbVie | Venclexta | $70 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · An Open Label, Single Arm, Investigator-Initiated Trial To Evaluate the Ability of Enasidenib To Decrease Red Blood Cell Transfusion-Dependence in Patients With Idh2 Wild-Type Myeloid Malignancies · 2024 | Their institution | $84,683 |
| Celgene Corporation · An Open Label, Single Arm, Investigator-Initiated Trial To Evaluate the Ability of Enasidenib To Decrease Red Blood Cell Transfusion-Dependence in Patients With Idh2 Wild-Type Myeloid Malignancies · 2023 | Their institution | $73,824 |
| Celgene Corporation · An Open Label, Single Arm, Investigator-Initiated Trial To Evaluate the Ability of Enasidenib To Decrease Red Blood Cell Transfusion-Dependence in Patients With Idh2 Wild-Type Myeloid Malignancies · 2025 | Their institution | $44,664 |
| Celgene Corporation · Phi Cc-486 Combo W/ Venetoclax in Aml (Cc-486-Aml-004 (Umbrella)) - A Phase 1b, Open-Label, Global, Multicenter, Dose Determination Study To Evaluate Safety, Tolerability, and Preliminary Efficacy of Cc-486 (Onureg ) in Combination Therapy in Subjects Wit · 2022 | Their institution | $28,902 |
| Celgene Corporation · Phi Cc-486 Combo W/ Venetoclax in Aml (Cc-486-Aml-004 (Umbrella)) - A Phase 1b, Open-Label, Global, Multicenter, Dose Determination Study To Evaluate Safety, Tolerability, and Preliminary Efficacy of Cc-486 (Onureg ) in Combination Therapy in Subjects Wit · 2023 | Their institution | $25,297 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1760771737
- Licence
- CA A130597California A130597: Current · expires 2027-08-31
- Trained
- University of Utah School of Medicine, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-03-30
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.